Mon Health Cancer Center now offers new targeted treatment for advanced prostate cancer

Vandalia Health Mon Health Cancer Center is expanding treatment options with PLUVICTO®, a breakthrough therapy giving men with advanced prostate cancer new possibilities for effective care.

PLUVICTO is designed for men who have metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and developed resistance to androgen deprivation therapy. Many patients who qualify have also already tried chemotherapy.

PLUVICTO is not chemotherapy. It’s a type of targeted radiation treatment that seeks out a specific marker called PSMA found on many prostate cancer cells. A PSMA-PET scan is used to check whether a patient’s cancer cells have enough of this marker for the treatment to work. If the scan shows the cancer is “PSMA positive,” PLUVICTO may be an option. The treatment is given intravenously and once in the body, it travels to the cancer cells, attaches to the PSMA marker, and delivers radiation directly to them while minimizing radiation exposure to nearby healthy tissue. Patients may be considered for PLUVICTO if their prostate cancer has spread, is resistant to androgen deprivation therapy, is confirmed as PSMA positive, and if they have previously been treated with androgen deprivation therapy and possibly chemotherapy.

“Introducing PLUVICTO is an important milestone in our ability to treat PSMA-positive metastatic prostate cancer,” said Benjamin Yan, MD, of Mon Health Cancer Center. “Its targeted approach enables us to deliver radiation selectively to cancer cells that have spread throughout the body, which is not possible with many traditional therapies. We’re pleased to make this advanced treatment accessible to our patients locally.”

PLUVICTO is given in a series of appointments at the Mon Health Cancer Center. A patient’s care team will determine the dose and schedule that are tailored to each individual patient and will offer support throughout the treatment process.